Preliminary Conference Program 2010

It Is All About Money: Creative and alternative sources of capital raising.
Biotech CEOs of both public and private companies are always in fund raising mode. How are they addressing their capital needs during this IPO drought and post the financial meltdown. What are they doing to gain favor with investors and keep their share prices up? How are private companies managing to raise capital when the market is locked down? This panel will address these questions and discuss creativity born from necessity.

Biotech in 2020: Seasoned industry veterans will discuss the future of the biotechnology industry and what they think it will look like in five, 10, 15 years.
Each of these panelists have been engaged in the biotech industry for 20 years or more. They have witnessed the industry grow from its earliest days, when an exit was an IPO and a deal with a pharma was automatic validation to today when biotech market caps are starting to rival the market caps of some pharmas.